Human Recombinant LILRB4 protein, ECD, His Tag (V2LY-0526-LY4982)

Name: Human Recombinant LILRB4 protein, ECD, His Tag
SKU: V2LY-0526-LY4982
Rating: 5 (1 reviews)

See all LILRB4 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant LILRB4 protein, ECD, His Tag consist of Amino Acid: 1-259 and predicts a molecular mass of 27.7 kDa.

Molecule Mass

27.7 kDa

Protein Domain

ECD

Verified

HPLC

Sequence

Amino Acid: 1-259

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

≥95% as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile PBS

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

Leukocyte Immunoglobulin Like Receptor B4

Function

Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462).
Receptor for FN1 (PubMed:34089617).
Receptor for apolipoprotein APOE (PubMed:30333625).
Receptor for ALCAM/CD166 (PubMed:29263213).
Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:9151699).
Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:19833736).
This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617).
Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:16493035, PubMed:19833736, PubMed:29263213).
Induces up-regulation of CD86 on dendritic cells (PubMed:19860908).
Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:11875462).

Biological Process

Adaptive immune responseIEA:UniProtKB-KW
Fc receptor mediated inhibitory signaling pathwayManual Assertion Based On ExperimentIDA:ARUK-UCL
Interleukin-10-mediated signaling pathwayManual Assertion Based On ExperimentIEP:ARUK-UCL
Negative regulation of activated T cell proliferationManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of chemokine productionManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of cytokine production involved in inflammatory responseManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of cytotoxic T cell differentiationManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of I-kappaB kinase/NF-kappaB signalingManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of interferon-gamma productionManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of interleukin-1 beta productionManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of interleukin-10 productionManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of interleukin-2 productionManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of interleukin-5 productionManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of interleukin-6 productionManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of IP-10 productionManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of MAPK cascadeManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of miRNA transcriptionManual Assertion Based On ExperimentIDA:BHF-UCL
Negative regulation of monocyte activationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of osteoclast differentiationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of protein localization to nucleusManual Assertion Based On ExperimentIDA:BHF-UCL
Negative regulation of protein tyrosine kinase activityManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of signaling receptor activityManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of T cell costimulationManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of T cell cytokine productionManual Assertion Based On ExperimentIDA:ARUK-UCL
Negative regulation of T cell proliferationManual Assertion Based On ExperimentIMP:ARUK-UCL
Negative regulation of T cell receptor signaling pathwayManual Assertion Based On ExperimentIDA:BHF-UCL
Negative regulation of tumor necrosis factor productionManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of CD8-positive, alpha-beta T cell differentiationManual Assertion Based On ExperimentIDA:ARUK-UCL
Positive regulation of regulatory T cell differentiationManual Assertion Based On ExperimentIDA:ARUK-UCL
Positive regulation of T cell anergyManual Assertion Based On ExperimentIMP:ARUK-UCL
Receptor internalizationManual Assertion Based On ExperimentIMP:ARUK-UCL
Tolerance inductionManual Assertion Based On ExperimentIDA:ARUK-UCL

Cellular Location

Cell membrane
Ligand binding leads to internalization and translocation to an antigen-processing compartment.

Topology

Extracellular: 22-259
Helical: 260-280
Cytoplasmic: 281-448

Liu, H., Yang, J., Zhang, J., Zhang, P., Zhang, M., Yang, C., ... & Yang, J. (2023). Molecular regulatory mechanism of LILRB4 in the immune response. Central European Journal of Immunology, 48(1).

Yang, T., Qian, Y., Liang, X., Wu, J., Zou, M., & Deng, M. (2022). LILRB4, an immune checkpoint on myeloid cells. Blood Science, 4(02), 49-56.

Singh, L., Muise, E. S., Bhattacharya, A., Grein, J., Javaid, S., Stivers, P., ... & Brandish, P. E. (2021). ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. Molecular Cancer Research, 19(4), 702-716.

Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021). LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. Journal of Experimental Medicine, 218(7), e20201811.

Churchill, H. R., Fuda, F. S., Xu, J., Deng, M., Zhang, C. C., An, Z., ... & Chen, W. (2021). Leukocyte immunoglobulin‐like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry Part B: Clinical Cytometry, 100(4), 476-487.

Liu, J., Wu, Q., Shi, J., Guo, W., Jiang, X., Zhou, B., & Ren, C. (2020). LILRB4, from the immune system to the disease target. American Journal of Translational Research, 12(7), 3149.

Li, Z., Deng, M., Huang, F., Jin, C., Sun, S., Chen, H., ... & Zhang, C. C. (2020). LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cellular & Molecular Immunology, 17(3), 272-282.

Gui, X., Deng, M., Song, H., Chen, Y., Xie, J., Li, Z., ... & An, Z. (2019). Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer immunology research, 7(8), 1244-1257.

Li, Q., Wei, G., & Tao, T. (2019). Leukocyte immunoglobulin-like receptor B4 (LILRB4) negatively mediates the pathological cardiac hypertrophy by suppressing fibrosis, inflammation and apoptosis via the activation of NF-κB signaling. Biochemical and biophysical research communications, 509(1), 16-23.

Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., ... & Zhang, C. C. (2018). LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 562(7728), 605-609.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant LILRB4 protein, ECD, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Human Recombinant LILRB4 protein, ECD, hFc Tag (CAT#: V2LY-0526-LY4980)

Human Recombinant LILRB4 protein, ECD, Biotin Conjugated, His & AVI Tag (CAT#: V2LY-0526-LY4981)

Human Recombinant LILRB4 protein, ECD, His Tag-1 (CAT#: V2LY-0526-LY4983)

Mouse Recombinant LILRB4 protein, ECD, His Tag (CAT#: V2LY-0526-LY8556)

Mouse Recombinant LILRB4 protein, hFc Tag (CAT#: V2LY-0526-LY8557)

Related Products

Mouse Recombinant LILRB4 protein, hFc Tag (CAT#: V2LY-0526-LY8557)

Mouse Anti-LILRB4 Recombinant Antibody (CBYJL-1697) (CAT#: CBMAB-L1576-YJ)

Mouse Recombinant LILRB4 protein, ECD, His Tag (CAT#: V2LY-0526-LY8556)

Mouse Anti-LILRB4 Recombinant Antibody (CBYJL-1695) (CAT#: CBMAB-L1574-YJ)

Mouse Anti-LILRB4 Recombinant Antibody (CBT3130) (CAT#: V2LY-0625-LY1597)

Armenian Hamster Anti-LILRB4 Recombinant Antibody (CBWJC-4124) (CAT#: CBMAB-C5468WJ)

Human Anti-LILRB4 Recombinant Antibody (CBXC-0716) (CAT#: CBMAB-C1830-CQ)

Mouse Anti-LILRB4 Recombinant Antibody (CBYY-I0760) (CAT#: CBMAB-I1687-YY)

Mouse Anti-LILRB4 Recombinant Antibody (ZM4.1) (CAT#: CBMAB-C12020-LY)

Human Recombinant LILRB4 protein, ECD, hFc Tag (CAT#: V2LY-0526-LY4980)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry